Article Text

Download PDFPDF

Considering IL-6
  1. Iain McInnes
  1. Correspondence to Professor Iain McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK, Iain.McInnes{at}glasgow.ac.uk

Statistics from Altmetric.com

Targeting interleukin (IL)−6 or its receptor for the treatment of inflammatory disease is an attractive approach to the management of complex inflammatory diseases, especially those with a systemic component to their presentation and comorbidity. Biological drugs that target IL-6 receptor are already in clinical practice. Recently, more agents are emerging from clinical trials that block distinct parts of the IL-6/IL-6R pathway.

In this edition, Jones et al explore the rich diversity of biology mediated by IL-6. …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.